Oddo Bhf set a €20.00 ($24.69) price objective on Evotec (ETR:EVT) in a research note released on Wednesday morning. The brokerage currently has a buy rating on the stock.

A number of other equities analysts also recently issued reports on EVT. Berenberg Bank set a €16.00 ($19.75) price target on Evotec and gave the stock a neutral rating in a research report on Wednesday, November 8th. Deutsche Bank set a €17.00 ($20.99) price target on Evotec and gave the stock a buy rating in a research report on Tuesday, December 5th.

Evotec (ETR EVT) opened at €15.85 ($19.57) on Wednesday. Evotec has a 12-month low of €7.66 ($9.46) and a 12-month high of €22.50 ($27.78). The stock has a market capitalization of $2,380.00 and a price-to-earnings ratio of 75.48.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/03/11/oddo-bhf-analysts-give-evotec-evt-a-20-00-price-target.html.

About Evotec

Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.